Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Germán Plascencia-Villa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Developmental and Regenerative Biology, The University of Texas at San Antonio (UTSA), San Antonio, TX 78249, USA. Hauptthemen laut MEDLINE: Mitochondria, Neurodegenerative Diseases. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lowe Foundation, Kleberg Foundation, Semmes Foundation.
Abstract (Originalsprache)
The progressive deterioration of function and structure of brain cells in neurodegenerative diseases is accompanied by mitochondrial dysfunction, affecting cellular metabolism, intracellular signaling, cell differentiation, morphogenesis, and the activation of programmed cell death. However, most of the efforts to develop therapies for Alzheimer’s and Parkinson’s disease have focused on restoring or maintaining the neurotransmitters in affected neurons, removing abnormal protein aggregates through immunotherapies, or simply treating symptomatology. However, none of these approaches to treating neurodegeneration can stop or reverse the disease other than by helping to maintain mental function and manage behavioral symptoms. Here, we discuss alternative molecular targets for neurodegeneration treatments that focus on mitochondrial functions, including regulation of calcium ion (Ca2+) transport, protein modification, regulation of glucose metabolism, antioxidants, metal chelators, vitamin supplementation, and mitochondrial transference to compromised neurons. After pre-clinical evaluation and studies in animal models, some of these therapeutic compounds have advanced to clinical trials and are expected to have positive outcomes in subjects with neurodegeneration. These mitochondria-targeted therapeutic agents are an alternative to established or conventional molecular targets that have shown limited effectiveness in treating neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Developmental and Regenerative Biology, The University of Texas at San Antonio (UTSA), San Antonio, TX 78249, USA.
ORCID-Profile: George Perry
Förderung
- Lowe Foundation
- Kleberg Foundation
- Semmes Foundation
- Alzheimer’s Association
- NIH National Institute on Aging
Zitieren
APA
Plascencia-Villa, G., & Perry, G. (2023). Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512486
Vancouver
Plascencia-Villa G, Perry G. Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512486
BibTeX
@article{PlascenciaVilla2023,
author = {Plascencia-Villa, Germán and Perry, George},
title = {Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512486}
}
EUVIMED